Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

930 - The mTOR kinase inhibitor AZD-2014 enhances the antitumor effects of XPO1 antagonist KPT-185 in mantle cell lymphoma


20 Dec 2015


Poster presentation 2


Kazumasa Sekihara


Annals of Oncology (2015) 26 (suppl_9): 37-39. 10.1093/annonc/mdv521


K. Sekihara1, S. Yamamoto1, M. Kikkawa2, H. Taka2, N. Kaga2, H. Matsushita3, H. Hayashi4, M. Tanaka4, T. Miida1, M. Andreeff5, M.Y. Konopleva5, Y. Tabe1

Author affiliations

  • 1 Department Of Clinical Laboratory Medicine, Juntendo University School of Medicine, 113-8421 - Tokyo/JP
  • 2 Laboratory Of Proteomics And Biomolecular Science, Biomedical Research Center, Juntendo University School of Medicine, 113-8421 - Tokyo/JP
  • 3 Department Of Laboratory Medicine, Tokai University School of Medicine Isehara Campus, Isehara/JP
  • 4 Support Center For Medical Research And Education, Tokai University School of Medicine Isehara Campus, Isehara/JP
  • 5 Department Of Leukemia, MD Anderson Cancer Center, Houston/US


Abstract 930


Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma characterized by the aberrant expression of several oncogenic effectors. The nuclear transporter exportin-1 (XPO1) is highly expressed in MCL andis associated with pathogenesis. The frequent activation of mTOR signaling, a central cellular metabolism regulator, is an important therapeutic target in MCL. In this study, we investigated the antitumor effects and molecular / metabolic changes of the combination of XPO1 antagonist KPT-185 with second generation mTOR kinase inhibitor AZD2014 on MCL.


Four MCL cell lines Z138, JVM2, MINO, and Jeko-1 were utilized. Cell viability was evaluated by MTT, cell counting and PI flow cytometric analysis. We then performed cDNA array, iTRAQ proteomic analysis, immunoblotting and metabolome analysis using CE-MS.


AZD2014 significantly enhanced the KPT-185-induced cell growth inhibition in the tested MCL cell lines.Transcriptomic analysis using cDNA array showed that KPT-185 / AZD-2014 affected expression of 137 genes (fold change > 2) in Jeko-1 cells. IPA analysis implicated the inhibition of STAT3 as one of the mechanistic leads. iTRAQ detected significant upregulation of glycolysis / gluconeogenesis pathways after KPT-185 treatment and KPT-185 / AZD-2014 repressed ribosomal biogenesis (KEGG analysis) with implicated activation of p53 and inhibition of p70 S6K and MYCN (IPA) in at least 2 of the 4 tested cell lines. We further found the downregulation of p-S6K and c-Myc and the upregulation of p27KIP and cleaved caspase-9 by immunoblotting. Of note, CE-MS demonstrated that the increase of lactic acid by KPT-185 was effectively reversed by AZD-2014, and that TCA cycle metabolites citric acid, succinic acid and malic acid were drastically decreased by KPT-185 / AZD-2014 combination.


Our findings indicated that inhibition of mTOR kinase enhances the antitumor effects of the XPO1 antagonist KPT-185 with effective repression of XPO1 blockage–induced glycolysis / gluconeogenesis upregulation. These findings suggest a novel promising combinatorial strategy targeting pro-survival metabolism in MCL.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings